FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS

被引：0
|
作者：
Salvatore, Lisa
Loupakis, Fotios [2 ]
Cremolini, Chiara
Schirripa, Marta
Masi, Gianluca [1 ]
Antoniotti, Carlotta
Fornaro, Lorenzo [1 ]
Sensi, Elisa [3 ]
Lupi, Cristiana [3 ]
Bergamo, Francesca [4 ]
Lonardi, Sara [4 ]
Zagonel, Vittorina [4 ]
Fontanini, Gabriella [3 ]
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Univ So Calif, Pisa, Italy
[3] Univ Pisa, Div Anat Patol, Dipartimento Chirurg, Pisa, Italy
[4] Ist Oncol Veneto IRCCS, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [2] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [4] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [5] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [6] REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Baldi, Giacomo Giulio
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Stasi, Irene
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Andreuccetti, Michele
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2009, 20
  • [7] Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI
    Vasile, E.
    Masi, G.
    Loupakis, F.
    Cupini, S.
    Baldi, G. G.
    Salvatore, L.
    Fornaro, L.
    Pfanner, E.
    Ricci, S.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [8] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [10] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Kito, Yosuke
    Satake, Hironaga
    Taniguchi, Hiroya
    Yamada, Takeshi
    Horie, Yoshiki
    Esaki, Taito
    Denda, Tadamichi
    Yasui, Hisateru
    Izawa, Naoki
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Mori, Keita
    Yamazaki, Kentaro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
12345